Skip to main navigation
Top Links - Left
BioNTech.com
Newsroom
Investors
Healthcare Professionals
English
Language switcher (Content)
English
German
Top Links - Right
Connect
Main Navigation
BioNTech.com
News
Events & Presentations
Financials
Financials
SEC Filings
Annual Reports
Quarterly Reports
Financial Calendar
Corporate Governance
Corporate Governance
Overview
Transparency
ESG
Stock Info
Stock Info
Stock Quote & Chart
Analyst Coverage
Shareholder Fraud Warning
Share Repurchase Program
Dividend Information
Investor FAQs
Annual General Meeting
Annual General Meeting
Annual General Meeting 2024
Annual General Meeting Archive
Contact Us
Newsroom
Investors
Healthcare Professionals
Breadcrumb
Investors
Search
Search
Filter by content type
(-)
News
(137)
Filter by content year
(-)
2022
(137)
Filter by form group
Filter by category
(-)
All
(137)
Collaborators
(91)
Other
(78)
Clinical
(34)
Events
(26)
Financial
(16)
Science
(15)
HR
(2)
Filter by category
Search
News
BioNTech veröffentlicht am 8. August 2022 Ergebnisse des zweiten Quartals sowie Informationen zum operativen Fortschritt
News
BioNTech to Report Second Quarter 2022 Financial Results and Operational Update on August 8, 2022
News
Pfizer und BioNTech treiben COVID-19-Impfstoffstrategie weiter voran: neue klinische Studie mit Impfstoffkandidaten der nächsten Generation mit verbessertem Design des Spike-Proteins begonnen
News
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
News
BioNTech und Genmab erweitern globale strategische Kollaboration zur Entwicklung und Vermarktung neuartiger Immuntherapiekandidaten
News
BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
News
BioNTech veröffentlicht Ergebnisse des zweiten Quartals 2022 und Informationen zur Geschäftsentwicklung
News
BioNTech Announces Second Quarter Financial Results and Corporate Update
News
Pfizer und BioNTech reichen Antrag für Notfallzulassung eines angepassten bivalenten COVID-19-Impfstoffs für Omikron-Varianten BA.4/BA.5 bei der FDA ein
News
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
Pagination
Page 1
Next page
››